Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Microbiology Reviews

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/CMR.00018-12PMID 22763632PMCID PMC3416489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Emergence of invasive pneumococcal disease caused by non-vaccine serotypes in the era of the 7-valent conjugate vaccine].

  2014cited by this paper
• Vaccines for preventing pneumococcal infection in adults.

  2013cited by this paper
• Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)

  2012cited by this paper
• Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.

  2011cited by this paper
• Applied time series analysis

  2011cited by this paper
• T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization.

  2011cited by this paper
• Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.

  2011cited by this paper
• A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children

  2011cited by this paper
• Invasive pneumococcal disease

  2011cited by this paper
• Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.

  2010cited by this paper
• Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.

  2010cited by this paper
• Sexually transmitted diseases treatment guidelines, 2010.

  2010cited by this paper
• Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

  2010cited by this paper
• Empyema Hospitalizations Increased in US Children Despite Pneumococcal Conjugate Vaccine

  2010cited by this paper
• Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis.

  2010cited by this paper
• Risk Factors for Invasive Pneumococcal Disease in Children in the Era of Conjugate Vaccine Use

  2010cited by this paper
• Declining invasive pneumococcal disease mortality in the United States, 1990-2005.

  2010cited by this paper
• Effect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis

  2010cited by this paper
• Preclinical Evaluation of the Pht Proteins as Potential Cross-Protective Pneumococcal Vaccine Antigens

  2010cited by this paper
• Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2010cited by this paper
• Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

  2010cited by this paper
• Streptococcus pneumoniae: virulence factors and variation.

  2010cited by this paper
• Serotype 19A Is the Most Common Serotype Causing Invasive Pneumococcal Infections in Children

  2010influential reference
• Occult Pneumococcal Bacteremia: A Review

  2010cited by this paper
• Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States.

  2010cited by this paper
• A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination.

  2010cited by this paper
• Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]

  2010cited by this paper
• Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.

  2009cited by this paper
• Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine

  2009cited by this paper
• Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2009cited by this paper
• Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young Children

  2009cited by this paper
• Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung.

  2009cited by this paper
• Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.

  2009cited by this paper
• Immunization with a Combination of Three Pneumococcal Proteins Confers Additive and Broad Protection against Streptococcus pneumoniae Infections in Mice

  2009cited by this paper
• Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006.

  2009cited by this paper
• Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine.

  2009cited by this paper
• Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.

  2009cited by this paper
• Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.

  2009cited by this paper
• Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.

  2009cited by this paper
• Association of Serotype of Streptococcus pneumoniae With Risk of Severe and Fatal Outcome

  2009cited by this paper
• The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of Immunogenicity

  2009cited by this paper
• Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection.

  2008cited by this paper
• Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults.

  2008cited by this paper
• Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

  2008cited by this paper
• Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.

  2008cited by this paper
• The changing epidemiology of pneumococcal pulmonary disease in the era of the heptavalent vaccine

  2008cited by this paper
• Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.

  2008cited by this paper
• Impact of conjugate pneumococcal vaccines on antibiotic resistance.

  2008cited by this paper
• Prevalence and risk factors for nasopharyngeal carriage of Streptococcus pneumoniae among adolescents.

  2008cited by this paper
• Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005.

  2008cited by this paper
• EPSTEIN-BARR VIRUS LOAD IN CEREBROSPINAL FLUID OF PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION

  2008cited by this paper
• Changing epidemiology of invasive pneumococcal disease: a complicated story.

  2008cited by this paper
• Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses.

  2008cited by this paper
• Vaccines for preventing pneumococcal infection in adults.

  2008cited by this paper
• Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States.

  2008cited by this paper
• Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies

  2008cited by this paper
• Impact of the Pneumococcal Conjugate Vaccine on Serotype Distribution and Antimicrobial Resistance of Invasive Streptococcus pneumoniae Isolates in Dallas, TX, Children From 1999 Through 2005

  2007cited by this paper
• Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection.

  2007cited by this paper
• Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era.

  2007cited by this paper
• Pneumococcal bacteremia in febrile infants presenting to the emergency department before and after the introduction of the heptavalent pneumococcal vaccine.

  2007cited by this paper
• Development of lactococcal GEM-based pneumococcal vaccines.

  2007cited by this paper
• The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease.

  2007cited by this paper
• Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).

  2007cited by this paper
• Increased Antimicrobial Resistance Among Nonvaccine Serotypes of Streptococcus pneumoniae in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States

  2007cited by this paper
• Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

  2007cited by this paper
• Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

  2007cited by this paper
• Vaccine Escape Recombinants Emerge after Pneumococcal Vaccination in the United States

  2007cited by this paper
• Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP.

  2007cited by this paper
• Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States.

  2007cited by this paper
• Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.

  2006cited by this paper
• Trends in invasive pneumococcal disease-associated hospitalizations.

  2006cited by this paper
• Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia.

  2006cited by this paper
• Streptococcus pneumoniae Serogroups 15 and 33: An Increasing Cause of Pneumococcal Infections in Children in the United States After the Introduction of the Pneumococcal 7-Valent Conjugate Vaccine

  2006influential reference
• Changing Epidemiology of Outpatient Bacteremia in 3- to 36-Month-Old Children After the Introduction of the Heptavalent-Conjugated Pneumococcal Vaccine

  2006cited by this paper
• Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.

  2006cited by this paper
• Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease.

  2006cited by this paper
• ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

  2006cited by this paper
• Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.

  2005cited by this paper
• Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.

  2005cited by this paper
• Epidemiological differences among pneumococcal serotypes.

  2005cited by this paper
• Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

  2004influential reference
• Levofloxacin-Resistant Invasive Streptococcus pneumoniae in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine

  2004cited by this paper
• Postlicensure Surveillance for Pneumococcal Invasive Disease After Use of Heptavalent Pneumococcal Conjugate Vaccine in Northern California Kaiser Permanente

  2004cited by this paper
• Post-PCV7 Changes in Colonizing Pneumococcal Serotypes in 16 Massachusetts Communities, 2001 and 2004

  2004cited by this paper
• Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

  2003cited by this paper
• A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

  2003cited by this paper
• Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

  2003cited by this paper
• Vaccines for preventing pneumococcal infection in adults.

  2003cited by this paper
• Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein – conjugated pneumococcal vaccine in Filipino infants

  2003cited by this paper
• Pneumococcal septic arthritis: review of 190 cases.

  2003cited by this paper
• Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence.

  2003cited by this paper
• Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae.

  2002cited by this paper
• Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants

  2002cited by this paper
• [Bacteremic pneumococcal pneumonia].

  2002cited by this paper
• Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

  2002cited by this paper
• Bacteremic pneumococcal pneumonia

  2002cited by this paper
• Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.

  2002cited by this paper
• Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers.

  2001cited by this paper
• Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

  2001cited by this paper
• Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.

  2000cited by this paper

• Invasive pneumococcal disease in children with acute lymphoblastic leukaemia

  2026cites this paper
• P-436. Epidemiology of Pediatric Invasive Pneumococcal Disease in an Inner-City Tertiary Care Center: A 13-Year Study and Post-Pandemic Insights

  2025cites this paper
• Commiphora myrrha extract protects pigeons from Eimeria labbeana-like-triggered inflammatory dysregulation

  2025cites this paper
• Enhancing Pneumococcal Vaccine Efficacy in Pediatric Patients with Asthma: Investigating Immune Response Modulation.

  2025cites this paper
• The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay.

  2025cites this paper
• Detection and Density of S. pneumoniae, Cytokine/Chemokine Levels and Mucosal Antibody Levels to Pneumococcus in Nasopharyngeal Samples During SARS-CoV-2 Respiratory Infection in Children.

  2025cites this paper
• Impact of the National Vaccination Strategy on the Prevalence of Streptococcus pneumoniae and Its Serotypes Among Clinically Healthy Children Under Six Years of Age During and After the COVID-19 Pandemic

  2025cites this paper
• Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews

  2025cites this paper
• Comparative analysis of Invasive Pneumococcal Disease (IPD) trends in the US

  2025cites this paper
• Pediatric Pleural Effusion and Pneumococcal Vaccination Trends in the Pre- and Post-COVID Era: A Single-Centre Retrospective Study

  2025cites this paper
• A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease.

  2025cites this paper
• Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward

  2025cites this paper
• Understanding healthcare providers’ preferred attributes of pediatric pneumococcal conjugate vaccines in the United States

  2024cites this paper
• Incidence of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study

  2024cites this paper
• Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998-2019.

  2024cites this paper
• Case Report: Hypocomplementemic urticarial vasculitis syndrome in a pediatric patient with complement factor 1 deficiency

  2024cites this paper
• Modeling conjugate vaccine and natural induced antibody correlates of protection for pneumococcal colonization and acute otitis media infection in young children.

  2024cites this paper
• Study of pediatric invasive pneumococcal disease in the 13-pneumococcal conjugated vaccine era.

  2024cites this paper
• Prediction of post-PCV13 pneumococcal evolution using invasive disease data enhanced by inverse-invasiveness weighting

  2024cites this paper
• Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods.

  2024cites this paper
• Orbital complications of pediatric acute rhinosinusitis in the pneumococcal conjugate vaccine era.

  2024cites this paper
• Chemical Synthesis of Truncated Capsular Oligosaccharide of Serotypes 6C and 6D of Streptococcus pneumoniae with Their Immunological Studies

  2024cites this paper
• State of pneumococcal vaccine immunity

  2024cites this paper
• Naturally-induced serum antibody levels in children to pneumococcal polysaccharide 15B that correlate with protection from nasopharyngeal colonization but anti-serotype 15B antibody has low functional cross-reactivity with serotype 15C.

  2023cites this paper
• Prediction of post-PCV13 pneumococcal evolution using invasive disease data enhanced by inverse-invasiveness weighting

  2023cites this paper
• Genomic analysis of Streptococcus pneumoniae serogroup 20 isolates in Alberta, Canada from 1993–2019

  2023cites this paper
• Monitoring the Serotype Prevalence of Streptococcus pneumoniae over a Decade in Iran: A Systematic Review and Meta-analysis.

  2023cites this paper
• [Dose-response relationship between age and Streptococcus pneumoniae vaccination coverage in kindergarten children].

  2023cites this paper
• Il nuovo vaccino coniugato antipneumococcico 15-valente per la prevenzione delle infezioni da S. pneumoniae in età pediatrica: una valutazione di HTA

  2023cites this paper
• C-Terminal Lysine Residue of Pneumococcal Triosephosphate Isomerase Contributes to Its Binding to Host Plasminogen

  2023cites this paper
• A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).

  2023cites this paper
• Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014–2018

  2023cites this paper
• Twenty-Five Year Trend Change in the Etiology of Pediatric Invasive Bacterial Infections in Korea, 1996–2020

  2023cites this paper
• Increase in prevalence of Streptococcus pneumoniae serogroup 24 in children upon introducing 13-valent pneumococcal conjugate vaccine in Japan

  2023cites this paper
• Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)

  2023cites this paper
• A cost-effectiveness analysis of pneumococcal conjugate vaccines in infants and herd protection in older adults in Colombia

  2023cites this paper
• Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population

  2023cites this paper
• Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data

  2022cites this paper
• Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolates collected from unvaccinated children with pneumonia at a province in central Vietnam

  2022cites this paper
• The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy

  2022cites this paper
• Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018

  2022cites this paper
• Pneumococcal Vaccine Recommendations for Old-Age Home Indian Residents: A Literature Review

  2022cites this paper
• Incidence of Hospitalisation and Emergency Department Visits for Pneumococcal Disease in Children, Adolescents, and Adults in Liguria, Italy: A Retrospective Analysis from 2012–2018

  2022cites this paper
• Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children

  2022cites this paper
• Exploration of Streptococcus core genome to reveal druggable targets and novel therapeutics against S. pneumoniae

  2022cites this paper
• Controlled Human Infection Models To Accelerate Vaccine Development

  2022cites this paper
• Invasive pneumococcal disease and long-term outcomes in children: A 20-year population cohort study

  2022cites this paper
• Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong

  2022cites this paper
• A Rare Case of Pneumococcal Appendicitis in a Child

  2022cites this paper
• The impact of pneumococcal conjugate vaccine on the prevalence and severity of hospitalizations for pneumonia in children

  2022cites this paper
• Streptococcus pneumoniae Serotypes Associated with Death, South Africa, 2012–2018

  2022cites this paper
• Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine

  2022cites this paper
• A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).

  2022cites this paper
• Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children

  2021cites this paper
• Clarithromycin Inhibits Pneumolysin Production via Downregulation of ply Gene Transcription despite Autolysis Activation

  2021cites this paper
• Prevalence of Invasive Streptococcus pneumoniae Infections among Iranian Children: A Systematic Review and Meta-Analysis

  2021cites this paper
• Vaccines: An Armament in Combating Antimicrobial Resistance.

  2021cites this paper
• Non-linear relationships between children age and pneumococcal vaccine coverage: Important implications for vaccine prevention strategies.

  2021cites this paper
• Respiratory Viral and Bacterial Factors That Influence Early Childhood Asthma

  2021cites this paper
• Economic Burden of Pneumococcal Disease in Individuals Aged 15 Years and Older in the Liguria Region of Italy

  2021cites this paper
• Clarithromycin Inhibits Pneumolysin Production via Downregulation of <italic toggle='yes'>ply</italic> Gene Transcription despite Autolysis Activation

  2021cites this paper
• Pherotypes in Streptococcus Pneumoniae and Role of CSP-1 and CSP-2 in Antibiotic Susceptibility and Resistance; Towards Development of Live Attenuated Vaccine Candidates in Inducing Netosis Based Acquired Immune Response

  2021cites this paper
• Clinical manifestations and outcome of viral acute lower respiratory infection in hospitalised children in Myanmar

  2021influential citation
• Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).

  2021cites this paper
• The Burden of Invasive Bacterial Disease and the Impact of 10-Valent Pneumococcal Conjugate Vaccine in Children <5 years hospitalized for Meningitis in Lusaka, Zambia, 2010–2019

  2021cites this paper
• Serum antibody levels to pneumococcal polysaccharides 22F, 33F, 19A and 6A that correlate with protection from colonization and acute otitis media in children.

  2021cites this paper
• A systematic review and meta-analysis of serotype distribution of Streptococcus pneumoniae in Iran: Practical evidences to optimizing local vaccination protocols.

  2020cites this paper
• Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

  2020cites this paper
• Pneumococcal Meningitis and its Sequelae – A Devastating CNS Disease

  2020cites this paper
• Influenza-like illness is associated with high pneumococcal carriage density in Malawian children

  2020cites this paper
• Emergence of Meningitis Caused by Nonvaccine Serotypes of Pneumococcus in Rural United States

  2020cites this paper
• Pneumococcal Diseases Caused by Serotype Replacement in Colombia: A Cost-Effectiveness Analysis of Pneumococcal Conjugate Vaccines in Infants and Its Herd Protection in Older Adults

  2020cites this paper
• Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease

  2020cites this paper
• Autolysin (lytA) recombinant protein: a potential target for developing vaccines against pneumococcal infections

  2020cites this paper
• A Cross-Reactive Protein Vaccine Combined with PCV-13 Prevents Streptococcus pneumoniae- and Haemophilus influenzae-Mediated Acute Otitis Media

  2019cites this paper
• INVITED REVIEW SERIES: PAEDIATRIC AND ADULT BRONCHIECTASIS

  2019cites this paper
• Paediatric community‐acquired bacteraemia, pneumococcal invasive disease and antibiotic resistance fell after the pneumococcal conjugate vaccine was introduced

  2019cites this paper
• Emergence of serotype 19A Streptococcus pneumoniae after PCV10 associated with a ST320 in adult population, in Porto Alegre, Brazil

  2019cites this paper
• Evolution of Penicillin Non-susceptibility Among Streptococcus pneumoniae Isolates Recovered From Asymptomatic Carriage and Invasive Disease Over 25 years in Brazil, 1990–2014

  2019cites this paper
• Pneumonia in Children

  2019cites this paper
• Oral Antibiotics for Treating Children With Community-Acquired Pneumonia Complicated by Empyema

  2019cites this paper
• Comparison of pneumococcal vaccination response in children with sickle cell disease: HbSS and HbSC.

  2019cites this paper
• Prevalence of nasopharyngeal carriage of Streptococcus pneumoniae in children 7 to 14 years in 2016: A survey before pneumococcal conjugate vaccine introduction in Iran

  2019cites this paper
• SIGNATURE APPROVAL FORM MULTIPLEX REAL TIME PCR and MELT CURVE ASSAY DEVELOPMENT FOR THE SIMULTANEOUS DETECTION AND IDENTIFICATION OF STREPTOCOCCUS PNEUMONIAE and STAPHYLOCOCCUS AUREUS

  2019cites this paper
• Expression of the Nontypeable Haemophilus influenzae Type IV Pilus Is Stimulated by Coculture with Host Respiratory Tract Epithelial Cells

  2019cites this paper
• Risk factor profiles and clinical outcomes for children and adults with pneumococcal infections in Singapore: A need to expand vaccination policy?

  2019influential citation
• Characterisation and activation of Foxp3+ and Tr1 regulatory T cells in nasopharynx-associated lymphoid tissue by S. pneumoniae

  2019cites this paper
• Investigation of Gram-negative bacterial surface glycans: characterisation of Moraxella bovis lipooligosaccharide and progress towards developing a Nontypeable Haemophilus influenzae/Moraxella catarrhalis vaccine candidate

  2019cites this paper
• Antibiotics Susceptability of Streptococcus pneumoniae Isolated from Single Tertiary Childrens' Hospital Since 2014 and Choice of Appropriate Empirical Antibiotics

  2019cites this paper
• Asthma and Invasive Pneumococcal Disease in the Age of Pneumococcal Conjugate Vaccines

  2019cites this paper
• Asthma and the Risk of Invasive Pneumococcal Disease: A Meta-analysis

  2019cites this paper
• The Best of All Worlds: Streptococcus pneumoniae Conjunctivitis through the Lens of Community Ecology and Microbial Biogeography

  2019cites this paper
• Isolation of Streptococcus pneumoniae from the sputum samples and their antimicrobial resistance in Biratnagar, Nepal

  2019cites this paper
• Cloning and Expression of GST-HMPREF0351_11084 Gene in JM105 Cells: A New Potential Protein Vaccine for Pneumococcal

  2018cites this paper
• Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys

  2018cites this paper
• Stroke in Pediatric Bacterial Meningitis: Population-Based Epidemiology.

  2018cites this paper
• Streptococcus pneumoniae outbreaks and implications for transmission and control: a systematic review

  2018cites this paper
• Recommendations and barriers to vaccination in systemic lupus erythematosus.

  2018cites this paper
• Emergence of Monkeypox—West and Central Africa, 1970–2017

  2018cites this paper
• Invasive Pneumococcal Disease in Children below 14 Years before and after the Introduction of Pneumococcal Conjugated Vaccine

  2018cites this paper